AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies

Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway

(2011) Thorsten Zenz et al.   CELL CYCLE

Mitochondrial Metabolism and Cancer

(2009) Frank Weinberg et al.   Annals of the New York Academy of Sciences

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

Treatment of fludarabine-refractory chronic lymphocytic leukemia

(2009) Apostolia-Maria Tsimberidou et al.   CANCER

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

(2009) Francesc Bosch et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

(2009) Niels S. Andersen et al.   JOURNAL OF CLINICAL ONCOLOGY

Update in the management of chronic lymphocytic leukemia

(2009) Kami J Maddocks et al.   Journal of Hematology & Oncology

AMPK and PPARδ Agonists Are Exercise Mimetics

(2008) Vihang A. Narkar et al.   CELL

Can Exercise Mimetics Substitute for Exercise?

(2008) Erik A. Richter et al.   Cell Metabolism

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation

(2008) Ralph J. DeBerardinis et al.   Cell Metabolism

Acadesine, an adenosine-regulating agent with the potential for widespread indications

(2008) Brian G Drew et al.   EXPERT OPINION ON PHARMACOTHERAPY

New Agents in the Treatment of CLL

(2008) S. O'Brien   Hematology-American Society of Hematology Education Program

Disease-Specific Complications of Chronic Lymphocytic Leukemia

(2008) C. Dearden   Hematology-American Society of Hematology Education Program